Ergomed (ERGO)

 

ERGO Share PerformanceMore

52 week high216.90 28/02/17
52 week low117.00 16/09/16
52 week change 69.55 (57.72%)
4 week volume177,196 28/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Ergomed completes study recruitment ahead of schedule

Ergomed has completed recruitment for its phase IIb proof-of-concept study for PeproStat, its innovative new coagulant, o...

Recruitment complete early for Phase IIb study

RNS Number: 8231L Ergomed plc 24 July 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat - Top line results expected in Q4 2017, six months earlier than anticipated - Faster than expected recruitment reflects Ergomed's strong CRO capabilities L...

Investor Meeting

RNS Number: 0817K Ergomed plc 04 July 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Investor meeting London, UK - 4 July 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is today hosting an investor meeting at it...

PeproStat study passes recruitment mid-point

RNS Number: 6561I Ergomed plc 21 June 2017 PRESS RELEASE FOR IMMEDIATE RELEASE PeproStat Phase IIb study passes recruitment mid-point ahead of schedule - Top line results brought forward to Q4 2017 London, UK - 21 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the...

Ergomed resolutions passed at AGM

Ergomed has confirmed that all resolutions proposed at its annual general meeting on Friday were passed. At 8:34am: (LON...

Result of AGM

RNS Number: 3958I Ergomed plc 16 June 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Results of 2017 Annual General Meeting London, UK -16 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces ...

Ergomed appoints CEO

Ergomed has appointed Dr Dan Weng as its new chief executive and a board director from 1 July. He will takeover the rol...

Appointment of CEO

RNS Number: 2665I Ergomed plc 16 June 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed strengthens executive team with appointment of Dr Dan Weng as CEO - Founder Dr Miroslav Reljanovic to become Executive Vice-Chairman London, UK - 16 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the pro...

Fundamental DataMore

P/E ratio146.192
EPS1.3
Dividend yield0 %

Equity Research (ERGO)

equity development
Ergomed Plc
08/05/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. Aeterna Zentaris, a co-development partner of...
equity development
Ergomed Plc
12/04/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. 2016 perfectly highlighted the strengths of the...
equity development
Ergomed Plc
25/01/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. The recent period end update for Ergomed confirmed...

Latest discussion posts More

  • Results webinar

    If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at ...
    22-Mar-2017
    equity_dev
  • See management present

    If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of ...
    17-Jan-2017
    equity_dev
  • Webinar with management

    We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around ...
    26-Sep-2016
    equity_dev

Users' HoldingsMore

Users who hold Ergomed also hold..
TREATT40%
PURPLEBRICKS30%
INSPIRED ENERGY30%
ID:ISIN:VGG9828A119430%
CENTRAL ASIA30%

Codes & Symbols

ISINGB00BN7ZCY67
SymbolsERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO